Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 4, 2010, Pages 721-724

  Hanamura, Miho ^a   Iwamoto, Takuya ^a   Soga, Norihito ^b   Sugimura, Yoshiki ^b   Okuda, Masahiro ^a  

^a MIE UNIVERSITY HOSPITAL   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Corticosteroid; Hypocalcemia; Prostate cancer; Risk factor; Zoledronic acid

Indexed keywords

CALCIUM; CORTICOSTEROID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPOCALCEMIA; INCIDENCE; MALE; MEDICAL RECORD; PATHOGENESIS; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CALCIUM; DIPHOSPHONATES; FEMALE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77950896483     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.721     Document Type: Article

References (17)

1. Major P., Lortholary A., Hon J., Abdi E., Mills G., Menssen H. D., Yunus F., Bell R., Body J., Quebe-Fehling E., Seaman J., J. Clin. Oncol., 19, 558-567 (2001).
2. Body J. J., Support Care Cancer, 14, 408-418 (2006).
3. Green J. R., Müller K., Jaeggi K. A., J. Bone Miner. Res., 9, 745-751 (1994).
4. Rosen L. S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M. A., Coleman R. E., Reitsma D. J., Chen B. L., Seaman J. J., Cancer, 98, 1735-1744 (2003).
5. Maalouf N. M., Heller H. J., Odvina C. V, Kim P. J., Sakhaee K., Endocr. Pract., 12, 48-53 (2006).
6. Breen T. L., Shane E., J. Clin. Oncol., 22, 1531-1532 (2004).
7. Mishra A., J. Postgrad. Med., 54, 237 (2008).
8. Chennuru S., Koduri J., Baumann M. A., Intern. Med. J., 38, 635-637 (2008).
9. Payne R. B., Little A. J., Williams R. B., Milner J. R., Br. Med. J., 4, 643-646 (1973).
10. Peter R., Mishra V., Fraser W. D., BMJ, 328, 335-336 (2004).
11. Comlekci A., Biberoglu S., Hekimsoy Z., Okan I., Piskin O., Sekeroglu B., Alakavuklar M., Intern. Med., 37, 396-397 (1998).
12. Reid I. R., Curr. Opin. Rheumatol., 15, 458-463 (2003).
13. Mazziotti G., Angeli A., Bilezikian J. P., Canalis E., Giustina A., Trends Endocrinol. Metab., 17, 144-149 (2006).
14. Kinoshita Y., Masuoka K., Miyakoshi S., Taniguchi S., Takeuchi Y., Bone, 42, 226-228 (2008).
15. Ziegler R., Kasperk C., Steroids, 63, 344-348 (1998).
16. Potts J. T. Jr., "Harrison's Principles of Internal Medicine," 16th ed., ed. by Kasper D. L., Fauci A. S., Longo D. L., Braunwald E., Hauser S. L., Jameson J. L., McGraw-Hill Companies, New York, 2005, pp. 2249-2250.
17. Tucci M., Mosca A., Lamanna G., Porpiglia F., Terzolo M., Vana F., Cracco C., Russo L., Gorzegno G., Tampellini M., Torta M., Reimondo G., Poggio M., Scarpa R. M., Angeli A., Dogliotti L., Berruti A., Prostate Cancer Prostatic Dis., 12, 94-99 (2009).